Endometriosis is defined as a condition with endometrium-like tissues migrating outside of the pelvic cavity. However, the mechanism of endometriosis is still unclear. Lactate can be covalently modified to lysine residues of histones and other proteins, which is called lactylation. The results showed that the higher level of lactate and lactate dehydrogenase A enhanced the histone H3 lysine 18 lactylation (H3K18lac) in ectopic endometrial tissues and ectopic endometrial stromal cells than that in normal endometrial tissues and normal endometrial stromal cells. Lactate promoted cell proliferation, migration, and invasion in endometriosis. Mechanistically, lactate induced H3K18lac to promote the expression of high-mobility group box 1 (HMGB1) in endometriosis, and HMGB1 knockdown significantly reduced the cell proliferation, migration, and invasion of the lactate-treated cells through the phosphorylation of AKT. In conclusion, lactate could induce histone lactylation to promote endometriosis progression by upregulating the expression of HMGB1, which may provide a novel target for the prevention and treatment of endometriosis.

Background: Cervical cancer is one of the major cancers that threaten the health of women. CircRNA is an important factor in the regulation of cancer development and progression. The role of circRNA in cervical cancer is less well studied. The aim of this study was to explore the mechanism of circRNA effects on cervical cancer using circRNA-seq technology to study the expression profile data of 9 pairs of primary cervical cancer and paracancerous tissues. Method: DESeq2 was used to analyse differentially expressed circRNA and mRNA in cervical cancer and para-cancerous tissues. MiRanda and TargetScan are used to predict miRNAs that interact with circRNAs and mRNAs and to construct circRNA-miRNA-mRNA regulatory networks. KEGG and GO are used for functional annotation of differentially expressed genes. TIDE, TIMER2.0 was used to assess the status of the tumour immune micro -environment in cervical cancer. GEPIA2 was used to validate the results of differential expression analysis. Results: We eventually obtained 22 differentially expressed circRNAs (7 up-regulated and 15 down-regulated) and 1834 differentially expressed genes (613 up-regulated and 1221 down-regulated). The results of the KEGG analysis showed that the differentially expressed genes were mainly enriched in cell cycle and cancer -related signalling pathways. The new circRNA: circZNF208 was identified to promote fibroblast proliferation by interfering with its downstream hsa-miR-324-3p regulating four downstream genes LPHN3. The level of fibroblast infiltration is implicated in the poor prognosis of cervical cancer. Conclusion: We have identified a novel circRNA: circZNF208 that can interfere with fibroblast proliferation in cervical cancer through a ceRNA regulatory network, thereby promoting fibroblast proliferation in cervical cancer and affecting the prognosis of cancer patients.

目的:延胡索酸水合酶(fumarate hydratase,FH)缺失型子宫平滑肌瘤临床少见,通过分析9例延胡索酸水合酶缺失型子宫平滑肌瘤患者的临床资料,探讨该疾病临床特征、诊治方法及随访要点.方法:搜集2020年5月至2021年4月南京医科大学第一附属医院确诊的9例FH缺失型子宫平滑肌瘤患者的临床资料并整理进行回顾性分析.结果:①病史特点:患者发病年龄轻,初次发现子宫肌瘤中位年龄23岁,多无月经异常,为体检或自扪及腹部包块发现.有肌瘤剔除手术史者6例,其中2例进行过3次肌瘤剔除术.②辅助检查:彩色多普勒超声检查均提示多发子宫肌瘤,少数提示有丰富血流信号.盆腔核磁共振检查多数提示子宫肌瘤,富于细胞可能.③手术治疗:均经腹行子宫切除术或子宫肌瘤剔除术,术中输血2例,进行盆腔粘连分离4例,肠粘连分离2例,1例出现膀胱损伤行修补.④病理诊断:常规病理诊断均提示为子宫平滑肌瘤,部分有富于细胞型.免疫组织化学病理诊断FH缺失型子宫平滑肌瘤.有3例外周血DNA样本检出FH基因变异.结论:FH缺失型子宫平滑肌瘤无明显特异性症状表现,对于肌瘤多发、发病年龄早、复发快的患者,建议术后病理加做免疫组化检查以明确是否为该疾病.对于有胚系FH基因变异者,建议密切随访泌尿系统影像学检查,以早期发现肾脏肿瘤.

Angiogenesis is a physiological process, where new blood vessels are formed from pre-existing vessels through the mechanism called sprouting. It plays a significant role in supporting tumor growth and is expected to provide novel therapeutic ideas for treating tumors that are resistant to conventional therapies. We investigated the expression pattern of angiogenesis-related genes (ARGs) in ovarian cancer (OV) from public databases, in which the patients could be classified into two differential ARG clusters. It was observed that patients in ARGcluster B would have a better prognosis but lower immune cell infiltration levels in the tumor microenvironment. Then ARG score was computed based on differentially expressed genes via cox analysis, which exhibited a strong correlation to copy number variation, immunophenoscore, tumor mutation load, and chemosensitivity. In addition, according to the median risk score, patients were separated into two risk subgroups, of which the low-risk group had a better prognosis, increased immunogenicity, and stronger immunotherapy efficacy. Furthermore, we constructed a prognostic nomogram and demonstrated its predictive value. These findings help us better understand the role of ARGs in OV and offer new perspectives for clinical prognosis and personalized treatment.

Bromodomain PHD finger transcription factor (BPTF) is a core subunit of the nucleosome-remodeling factor (NURF) complex, which plays an important role in the development of several cancers. However, it is unknown whether BPTF regulates the progression of ovarian cancer (OC). To investigate this, we measured the relative expression levels of BPTF in OC cell lines and tissues using Western blot and immunohistochemistry, respectively, and the results were analyzed using the χ2 test. We also examined the effects from BPTF knockdown on the proliferation, migration, invasiveness, and apoptosis of OC cell lines. Mechanistic studies revealed that these effects were achieved through simultaneous modulation of multiple signaling pathways. We found that BPTF was highly expressed in OC cell lines and tissues compared with a normal human ovarian epithelial cell line and non-cancerous tissues (P < 0.05). These results are also supported by the public RNA-seq data. BPTF overexpression was correlated with a poor prognosis for OC patient survival (P < 0.05). In vitro experiments revealed that the downregulation of BPTF inhibited OC cell proliferation, colony formation, migration, and invasiveness, and induced apoptosis. BPTF knockdown also affected the epithelial-mesenchymal transition (EMT) signaling pathways and induced the cleavage of apoptosis-related proteins. Consequently, BPTF plays a critical role in OC cell survival, and functions as a potential therapeutic target for OC.

目的:通过分析ⅠB～ⅡA1期宫颈癌术后具有中危因素患者进行单纯化疗或放疗的预后和生活质量,探讨此类患者术后单纯辅助化疗的可行性.方法:对2010年1月至2017年6月在南京医科大学第一附属医院妇产科接受宫颈癌根治术的术后病理具有中危因素的ⅠB～ⅡA1期患者113例进行回顾性分析.根据术后辅助治疗方式分为化疗组56例,放疗组57例,比较两组患者治疗后疗效以及生活质量的差异.结果:化疗组和放疗组在平均年龄、病理类型和临床分期上均没有统计学差异.化疗组患者3年无瘤生存率和总生存率分别为92.8％和96.4％,放疗组患者3年无瘤生存率和总生存率分别为91.2％和96.5％,两组比较均无统计学差异(P＞0.05).化疗组在躯体功能、角色功能、社会功能、食欲及总体生活质量方面均优于放疗组.在不良反应方面,化疗组出现淋巴水肿、绝经症状的概率均低于放疗组,差异有统计学意义(P ＜ 0.05).化疗组的性生活保持率(66.1％,37/56)高于放疗组(40.4％,23/57),性满意度也显著高于放疗组(P ＜ 0.05),而放疗组患者更容易出现性焦虑和性生活障碍(P＜0.05).结论:对ⅠB～ⅡA1期宫颈癌根治术后具有中危因素的患者,采用单纯辅助化疗也可获得较好疗效,总体生活质量优于放疗患者.

目的 探讨左炔诺孕酮宫内缓释系统(LNG-IUS)治疗早期子宫内膜样腺癌(EEC)及子宫内膜不典型增生(EAH)的临床疗效.方法 收集采用LNG-IUS治疗的10例EEC患者及31例EAH患者的临床资料,分析其疗效、治疗后妊娠及复发情况.结果 所有患者治疗12个月时的完全缓解(CR)率为100％;治疗3、6、9、12个月时的EEC患者及EAH患者CR率比较均无统计学差异(P＞0.05).治疗＞3个月CR的EAH患者的月经紊乱比例高于治疗3个月CR者(P＜0.05).治疗后,妊娠并活产率为20.6％,复发率为7.3％.结论 LNG-IUS治疗EEC及EAH安全、有效,治疗后应积极助孕,减少复发.

LBX2‐AS1 is a long non‐coding RNA that facilitates the development of gastrointestinal cancers and lung cancer, but its participation in ovarian cancer development remained uninvestigated. Clinical data retrieved from TCGA ovarian cancer database and the clinography of 60 ovarian cancer patients who received anti‐cancer treatment in our facility were analysed. The overall cell growth, colony formation, migration, invasion, apoptosis and tumour formation on nude mice of ovarian cancer cells were evaluated before and after lentiviral‐based LBX2‐AS1 knockdown. ENCORI platform was used to explore LBX2‐AS1‐interacting microRNAs and target genes of the candidate microRNAs. Luciferase reporter gene assay and RNA pulldown assay were used to verify the putative miRNA‐RNA interactions. Ovarian cancer tissue specimens showed significant higher LBX2‐AS1 expression levels that non‐cancerous counterparts. High expression level of LBX2‐AS1 was significantly associated with reduced overall survival of patients. LBX2‐AS1 knockdown significantly down‐regulated the cell growth, colony formation, migration, invasion and tumour formation capacity of ovarian cancer cells and increased their apoptosis in vitro. LBX2‐AS1 interacts with and thus inhibits the function of miR‐455‐5p and miR‐491‐5p, both of which restrained the expression of E2F2 gene in ovarian cancer cells via mRNA targeting. Transfection of miRNA inhibitors of these two miRNAs or forced expression of E2F2 counteracted the effect of LBX2‐AS1 knockdown on ovarian cancer cells. LBX2‐AS1 was a novel cancer‐promoting lncRNA in ovarian cancer. This lncRNA increased the cell growth, survival, migration, invasion and tumour formation of ovarian cancer cells by inhibiting miR‐455‐5p and miR‐491‐5p, thus liberating the expression of E2F2 cancer‐promoting gene.

Purpose Platinum resistance is a primary barrier to improving the survival rate of ovarian cancer. The relationship between mtDNA somatic mutations and response to platinum-based chemotherapy in ovarian cancer has not been well clarified. Patients and Methods Here, we employed the next-generation sequencing (NGS) platform to identify mtDNA mutations of the unrelated high-grade serous ovarian cancer (HGSOC) patients. Results We identified 569 germline variants and 28 mtDNA somatic mutations, and found the platinum-sensitive relapsed HGSOC patients had more synonymous mutations while the platinum-resistant relapsed HGSOC patients had more missense mutations in the mtDNA somatic mutations. Meanwhile, we found that the HGSOC patients who harbored heteroplasmic pathogenic mtDNA somatic mutations had significantly higher prevalence of both platinum-resistance and relapse than those without (80.0% versus 16.7%, p=0.035). Additionally, we observed that the tumor tissues had significantly higher lactate-to-pyruvate (L/P) ratio than the paired nontumor tissues (p<0.001), and L/P ratio of tumors with any heteroplasmic pathogenic mtDNA mutations was significantly higher than that of the tumors free of pathogenic mtDNA mutations (p=0.025). Conclusion Our findings indicate that these heteroplasmic pathogenic mtDNA somatic mutations may cause decreased respiratory chain activity and lead to the metabolism remodeling that seem to be beneficial for progression of both platinum-based chemotherapy resistance and relapse.

目的:探讨防宫腔粘连隔离器(简称隔离器)用于宫腔粘连分离术后预防再粘连的有效性及安全性,评价隔离器在宫腔粘连分离术后维持宫腔正常形态的优势.方法:选取2015年8月至2017年2月在南京医科大学第一附属医院接受治疗的中重度宫腔粘连(宫腔粘连评分≥5分)患者60例.将患者随机分为隔离器组30例(宫腔粘连分离术后宫腔放置隔离器)和宫内节育器组30例(术后宫腔放置Tcu380宫内节育器),两组患者术后均行雌孕激素序贯治疗,4周后行二次宫腔镜探查术.比较两组患者的宫腔粘连评分下降情况、月经改善情况、妊娠结局及放置后副反应,所有患者术后随访2年.结果:隔离器组患者的宫腔粘连评分术前(9.5±2.0)分,二次宫腔探查时(0.7±1.0)分,差异有统计学意义(P<0.01);节育器组术前(8.7±1.9)分,二次宫腔探查时(3.7±2.7)分,差异有统计学意义(P<0.01);隔离器组二次宫腔探查时宫腔粘连评分明显小于节育器组评分,差异有统计学意义(P<0.01).隔离器组和节育器组二次宫腔探查时宫腔粘连评分≥5分发生率分别为0(0/30)和43％(13/30),两组比较差异有统计学意义(P<0.01);月经改善率分别为60％(18/30)和47％(14/30),两组比较差异无统计学意义(P=0.301).随访2年,隔离器组和节育器组的妊娠率比较,差异均无统计学意义(47％vs 43％,P=0.795).隔离组和节育器组的术后阴道出血时间比较,差异均无统计学意义[(6±3)天vs(5±2)天,P=0.078].两组患者术后均未出现发热、泌尿生殖道感染、过敏反应、腹痛、子宫穿孔、隔离器或节育器下移或脱落、带器妊娠等副反应.结论:隔离器用于中重度宫腔粘连分离术后预防宫腔再粘连无明显副反应,在维持术后宫腔正常形态及减少术后再粘连方面有独特优势,在术后月经恢复方面及妊娠结局的改善方面与节育器组无显著差异.

子宫颈管粘连是子宫颈环形电极切除术(LEEP)术后并发症之一,可致患者经血排出不畅、周期性腹痛、继发性闭经、盆腔子宫内膜异位症等,同时降低术后随访时子宫颈细胞学取材及阴道镜检查的满意度.子宫颈管重度粘连、完全封闭者需要手术干预.本文报道1例哺乳期行LEEP术后发生重度子宫颈管粘连,月经复潮后出现宫腔、输卵管积血及盆腔子宫内膜异位症的病例,并结合相关文献复习,以期加深认识、积累临床经验.

目的:分析左炔诺孕酮宫内缓释系统(levonorgestrel-releasing intrauterine system,LNG-IUS)的取出原因及使用满意度,探讨如何提高续用率,加强对使用LNG-IUS患者的管理.方法:对2015年1月-2018年6月南京医科大学第一附属医院自愿取出LNG-IUS的407例患者的资料进行回顾性分析,按初始放置LNG-IUS的原因分为避孕组及治疗组,对比两组妇女取出LNG-IUS的原因及上环期间的满意度.结果:上环期间两组均无妊娠发生.两组首要取器原因均为因症取器,闭经及阴道点滴出血为主要原因.而治疗组的续用率及满意率均显著高于避孕组(P＜ 0.05).与治疗组相比,避孕组有更多比率的妇女因激素相关不良反应而取器(JP＜0.05),主要为面部痤疮和色素沉着(P＜0.05).在因闭经取器妇女中,治疗组的置环时间及满意率显著大于避孕组(P＜0.05).结论:针对不同临床应用LNG-IUS人群,需给予不同的指导策略,包括上环前详细告知各种不良作用、上环后做好随访并及时处理各种不良反应及并发症,以期减少取器率,提高满意率.

Background and purpose: To evade immune defense, cancer cells can employ extracellular vesicles (EVs) to inhibit the anti-tumor activity of lymphocytes in the tumor microenvironment. However, the mechanisms and key molecules that mediate the effects of EVs on lymphocytes are unclear. Patients and methods: We used Quantibody® Human Cytokine Antibody Array 440 to determine the tumor immunity-related cytokine profile of peripheral blood lymphocytes (PBLs) stimulated with EVs derived from peritoneal washes or malignant ascites. We detected 21 upregulated and 27 downregulated proteins, including the immunosuppressive receptors Siglec-10, SLAM, PD-1, and TIM-3. Results: Flow cytometry analysis of PBLs or ovarian cancer ascites suggested that Siglec-10 expression on CD3+ T cells was higher in ovarian cancer patients than in healthy controls and in the malignant ascites of ovarian cancer patients than in their blood. Moreover, the expression of CD24, the Siglec-10 ligand, was associated with tumor stage and cancer cell metastasis. Finally, compared to the benign peritoneal wash-derived EVs, the malignant EVs significantly upregulated Siglec-10 expression on Jurkat T cells, inhibited the protein kinase C activity induced by phorbol 12-myristate 13-acetate and ionomycin, and impaired the phosphorylation of the tyrosine kinase ZAP-70 activated by crosslinking with an anti-CD3 antibody. Conclusion: The EVs secreted by malignant ovarian cells upregulated Siglec-10 expression on T cells and impaired T cell activation in the tumor microenvironment. We believe that a comprehensive understanding of the regulation of Siglec-10 and CD24 by malignant EVs has clinical importance, as it will aid in the development of better immunotherapeutic strategies for ovarian cancer.

Abstract Background Although high‐risk human papillomavirus (HR‐HPV) infection is recognized as the main cause of cervical cancer, only a minority of HPV‐infected women develop this malignancy. Increasing evidence suggests that alterations of telomere length might be implicated in carcinogenesis. However, the association between cervical cancer and telomere length remains unknown. Methods This case‐control study included 591 cervical cancer patients and 373 cancer‐free controls, all of whom were infected with HR‐HPV. Relative telomere length (RTL) in cervical cancer exfoliated cells was measured by quantitative PCR. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by logistic regression analysis. Results HPV16, 18, 52, and 58 were common in both case and control groups. The proportion of HPV16 infection tended to increase across the quartiles of RTL (Ptrend < 0.001). There was no statistically significant association of RTL with tumor differentiation, histological type, and FIGO stage. After adjustment for age and HPV types, the lowest quartile of RTL presented a 49% lower risk (OR = 0.51, 95% CI: 0.35, 0.76; P < 0.001) than those with the highest quartile of RTL. There was also a dose‐response relationship of shorter RTL on lower risk of cervical cancer (Ptrend < 0.001). Conclusion Shortened telomere length in cervical exfoliated cells was related to the lower risk of cervical cancer among HR‐HPV‐positive women, which might help to improve cervical cancer screening and surveillance. Further prospective studies with large sample should be designed to validate our preliminary findings, and evaluate the potential efficacy of telomere length for cervical cancer screening.

[目的]探讨子宫内膜复杂性不典型增生及早期子宫内膜癌患者保留治疗的完全缓解率、复发率和妊娠情况.[方法]回顾性分析2015年1月至2018年10月我院妇产科收治106例子宫内膜复杂性不典型增生或早期子宫内膜癌患者保守治疗情况,分析其治疗疗效、复发和妊娠情况,并分析影响子宫内膜复杂性不典型增生及早期子宫内膜癌患者保守生育功能治疗后完全缓解、复发和妊娠的因素.[结果]经保守治疗后完全缓解率为83.96％ (89/106),完全缓解后复发率为23.60％(21/89),妊娠率为35.96％(32/89).BMI≥30kg/m2是影响完全缓解(OR=2.031,95％CI:1.163～6.032)和完全缓解后复发(OR=1.325,95％CI:1.033～4.251)]、完全缓解后妊娠(OR=1.625,95％CI:1.235～5.621)的独立因素.BMI＜30kg/m2(OR=1.705,95％CI:1.511～4.981)、采用辅助生殖技术(OR=2.009,95％CI:1.735 ～6.235)可提高完全缓解后妊娠率.[结论]子宫内膜复杂性不典型增生及早期子宫内膜癌患者采用保守治疗可获得满意疗效.肥胖是影响保守治疗疗效、复发的主要因素,积极控制肥胖,采取辅助生殖技术可提高妊娠率,降低复发.

目的 研究分析吉西他滨联合同步放化疗方案在晚期宫颈癌治疗中的应用价值.方法 选取本院2015年3月至2018年6月收治的晚期宫颈癌患者50例作为本次研究对象,按照治疗方案将患者分为两组,两组均给予同步放化疗治疗,观察组联合吉西他滨治疗,对照组联合奈达铂治疗,比较两组晚期宫颈癌患者的治疗效果.结果 两组晚期宫颈癌患者的近期疗效,不良反应发生率,生活质量评分比较,差异具有统计学意义(P<0.05).结论 晚期宫颈癌患者应用吉西他滨联合同步放化疗治疗,疗效更为确切,对生活质量影响不大,值得在临床推广.

Objective: This meta-analysis aims to examine whether the MspI and Ile462Val polymorphisms of cytochrome P450 1A1 (CYP1A1) are associated with cervical cancer risk. Methods: Eligible case–control studies were identified dated until July 2017. Pooled odds ratios (ORs) were used to assess the strength of the association between the two variants and cervical cancer risk. Results: Thirteen studies were eligible (2148 cases and 2252 controls) concerning MspI polymorphism and 8 studies were eligible (1466 cases and 1690 controls) for Ile462Val polymorphism. MspI polymorphism seemed to result in cervical cancer risk in any genetic model (C allele vs T allele: OR=1.44, 95% confidence interval [CI]=1.16–1.79; heterozygous model: OR=1.40, 95% CI= 1.08–1.82; homozygous model: OR=2.22, 95% CI=1.48–3.33, dominant model: OR=1.50, 95% CI=1.14–1.98 and recessive model: OR=1.80, 95% CI=1.35–2.41); similar significantly increased risk was found among Caucasians and Asians. Ile462Val polymorphism was associated with elevated cervical cancer risk (Val allele vs Ile allele: OR=1.85, 95%CI=1.27–2.67; heterozygous model: OR=1.42, 95%CI=1.28–1.61; homozygousmodel: OR=2.94, 95%CI=1.15–7.54; dominant model: OR=2.00, 95%CI= 1.33–3.00); this finding was replicated upon Caucasian population. Conclusion: This meta-analysis demonstrated that polymorphisms in MspI and Ile462Val of CYP1A1 were risk factors for developing cervical cancer. Abbreviations: CYP1A1 = Cytochrome P450 1A1, HPV = human papillomavirus.

Objective:To investigate the characteristics of lymphatic metastasis of locally advanced cervical cancer (LACC) and to evaluate prognostic significance of neoadjuvant chemotherapy (NACT) in patients with LACC (FIGO IB2/ⅡA2).Methods:Retrospectively analyze the clinical records and follow-up information of 424 patients with cervical cancer or adenocarcinoma (FIGO ⅠA2-ⅡA2) after radical hysterectomy in Department of Gynecology,Jiangsu Provincial People's Hospital From January 2008 to December 2016.Results:In total,424 patients with cervical cancer were enrolled in the study.Of the 100 patients with LACC,68 patients underwent direct radical surgery,and 32 patients underwent radical cervical squamous cell carcinoma after 1-2 interventions or neoadjuvant chemotherapy.cervical squamous cell carcinoma after 1-2 interventions or neoadjuvant chemotherapy.pelvic lymph node metastasis in 20 cases,and paraaortic lymph node metastasis was not found.Univariate analysis revealed that deep muscular layer invasion and lymph vascular space invasion (LVSI) was associated with lymph node metastasis (P＜0.05).Histological type,degree of differentiation and whether neoadjuvant chemotherapy were not associated with lymph node metastasis (P＞0.05).Statistically significant single factor Logistic regression analysis showed that LVSI was an independent risk factor for lymph node metastasis (P＜0.05).There was no significant difference of lymphatic metastasis rate between NACT group and RS group (22.2％ vs.17.2％,P＞0.05).The disease-free survival and overall survival of the LACC group were significantly lower than those of the early cervical cancer group.The NACT group has lower postoperative infection rate,shorter operating duration and less time to keep the abdominal drainage,but there was no statistic significance between the two groups (P＞0.05),and intraoperative ureteral stenting rate,blood transfusion rate and incidence of other adjacent organ injuries were similar in the 2 groups.Conclusions:Locally advanced cervical cancer has poorer prognosis with significantly higher lymphatic metastasis rate than early cervical cancer.Pelvic lymph nodes metastasis was mainly correlated with LVSI and deep muscular layer involvement.Weather neoadjuvant chemotherapy infects the prognosis of advanced cervical cancer is unclear,and there is no evidence that neoadjuvant chemotherapy affects the detection rate of pelvic lymph node metastases.A larger sample or multicenter study is needed in the incidence of surgical-related complications.

Cervical cancer is the third most common type of cancer in women, and microRNAs play an important role in this type of cancer. The elevated expression of miR-146a is involved in the pathogenesis of cancers generally, but its role in cervical cancer has not been fully elucidated. In the present study, we assessed the expression of miR-146a in G>C polymorphisms and confirmed that the overexpression of miR-146a promoted cervical cancer cell viability. The recombinant expression plasmids pre-miR-146a-G or pre-miR-146a-C including single nucleotide polymorphisms (SNP) were successfully constructed. Pre-miR-146a-G or pre-miR-146a-C was transfected into cervical cancer cells or immortalized non-tumorigenic cells and the expression of miR-146a was evaluated by real-time PCR. The cell viability, cell-cycle analysis and apoptosis were assessed using Cell Counting Kit-8 assay (CCK-8), flow cytometry and cleaved caspase-3 protein expression, respectively. The expression of interleukin 1 receptor associated kinase 1 (IRAK1), TNF receptor-associated factor 6 (TRAF6) and cyclin D1 was assessed following the transfection with a miR-146a mimic or a negative control. The cell viability and the number of S-phase cells increased after transfection with miR-146a mimic or an IRAK1 or TRAF6 interference fragment. After transfection, IRAK1 and TRAF6 protein expression was downregulated and the expression of cyclin D1 was upregulated, however apoptosis and cleaved caspase-3 were not affected. Polymorphisms in miR-146a precursor may be linked to the expression of miR-146a and may be a potential target for cervical cancer therapy.